BioSpace News Archive

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), today announced the initiation of a Phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with Adjustment Disorder with Anxiety (AjDA).

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for third quarter ended September 30, 2021.

Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that the company is expanding its CDMO service offering into the rapidly growing cell and gene therapy market.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today presented the first-ever data on the health related quality of life (HRQOL) and experience of patients with obesity due to POMC or LEPR deficiency and updated results from the Uncovering Rare Obesity® (URO) genetic testing program at the Obesity Medicine Association’s Overcoming Obesity 2021 Conference and its Digital Experience (DX) Oct. 14-23.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases underserved by today’s therapies, announced today the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA).

OpGen, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 150,000 shares of convertible preferred stock

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today its first-in-class once-daily oral capsule AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), which was approved by the U.S. Food and Drug Administration (FDA) in March 2021.

Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published absolute efficacy data on the company’s cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint.

Insmed Incorporated today announced that it will release its third quarter 2021 financial results on Thursday, October 28, 2021 .

Pillar Biosciences today announced that it has entered into an agreement with Labcorp to provide genomic testing for people with cancer.